drugset / Trial / NCT03890952
Translational Study of Nivolumab in Combination With Bevacizumab for Recurrent Glioblastoma
Phase 2
Completed
40 enrolled
Ulrik Lassen
Herlev Hospital · collabUniversity of Copenhagen · collab
Non-randomizedParallel-groupOpen-labelBasic science
Summary
The aim of this study is to make preliminary assessment of PD-L1 and other immune related biomarkers that might act as predictors of anti-tumor activity of Nivolumab in patients with recurrent glioblastoma
Timeline
- Start
- 2018-10-01
- Primary completion
- 2023-02-01
- Completion
- 2024-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | — | — |
| Subject | Nivolumab | Monoclonal antibody | — | — |